Steinhorn B, Eroglu E, Michel T. Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:551-571. doi: 10.1146/annurev-pharmtox-012221-082339. Epub 2021 Sep 16. PMID: 34530645. PubMed link

Waldeck-Weiermair M, Yadav S, Spyropoulos F, Krüger C, Pandey AK, Michel T. Dissecting in vivo and in vitro redox responses using chemogenetics. Free Radic Biol Med. 2021 Nov 6:S0891-5849(21)00793-0. doi: 10.1016/j.freeradbiomed.2021.11.006. Epub ahead of print. PMID: 34752919. PubMed link

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30. PMID: 32227760; PMCID: PMC7121452.  PubMed link

Sorrentino A, Michel T. Redox à la carte: Novel chemogenetic models of heart failure. Br J Pharmacol. 2020 Jul;177(14):3162-3167. doi: 10.1111/bph.15093. Epub 2020 Jun 3. PMID: 32368791; PMCID: PMC7312266. PubMed link
Eroglu E, Michel T, Graier WF, Malli R. Nitric oxide sensors: Yes (again) to local NO.  Nature Chem Biol 2020, 16:606-607.

Lamas S and Michel T. Introduction to redox regulation of cardiovascular signaling. Free Radic Biol Med 2017; 109:1-3.

Kinlay  S, Michel T,  Leopold J. The future of vascular medicine. Circulation 2016; 133:2603-9.

Steinhorn BS, Loscalzo J, Michel T. Nitroglycerin and Nitric Oxide–A Rondo of Themes in Cardiovascular Therapeutics. N Engl J Med. 2015 Jul 16;373(3):277-80. doi: 10.1056/NEJMsr1503311. PMID: 26176386; PMCID: PMC4836444. PubMed link

Michel T.  R is for Arginine. Circulation 2013, 128:1400-1404. PubMed link

Sartoretto JL, Kalwa H, Romero N, Michel T. In vivo imaging of nitric oxide and hydrogen peroxide in cardiac myocytes. Methods Enzymol. 2013;528:61-78. doi: 10.1016/B978-0-12-405881-1.00004-5. PMID: 23849859. PubMed link

Maron BA and Michel T.  Subcellular localization of oxidants and regulation of endothelial nitric oxide synthase.  Circulation Journal 2012, 76 :2497-2512. PMID: 23075817

Michel T.  NO way to relax : the complexities of coupling nitric oxide synthase pathways in the heart.  Circulation 2010, 121:484-486.

Michel T and Vanhoutte PM.  Cellular signaling and NO production.  Pflügers Archiv Pharm, 2010, 459:807-816.

Igarashi J and Michel T. Sphingosine 1-phosphate and control of vascular tone. Cardiovascular Research 2009, 82 :212-220.

Michel, T.  Nitric oxide synthase 3. UCSD-Nature Molecule Pages 2009 (doi:10.1038/mp.a001660.01).

Igarashi J, Michel T. S1P and eNOS regulation. Biochim Biophys Acta 2008 1781:489-95.

Igarashi J and Michel T. The enigma of sphingosine 1-phosphate synthesis: A novel role for endothelial sphingosine kinases. Circulation Research 2008, 102:630-2.

Lamas, S, Lowenstein CJ and Michel T. Nitric oxide signaling comes of age: 20 years and thriving.  Cardiovascular Research 2007, 75:1-3.

Dudzinski D and Michel T.  Life history of eNOS: Partners and pathways.  Cardiovascular Research 2007, 75:247-60.

Mitchell, DA, Michel T and Marletta M. Effects of S-nitrosation of nitric oxide synthase.  Adv Exp Biol 2007, 1:141-179.

Lowenstein, C and Michel T.  What’s in a name?  eNOS and anaphylactic shock. J Clin Invest, 2006, 116:2075-8.

Dudzinski D, Igarashi J, Greif D and Michel T.  Pharmacology and molecular regulation of nitric oxide synthases.  Annu Rev Pharmacol Toxicol, 2006, 46:235-76.

Igarashi J and Michel T. More sweetness than light?  A search for the causes of diabetic vasculopathy.  J Clin Invest 2001; 108:1425-7.

Michel T.  Targeting and translocation of endothelial nitric oxide synthase.  Braz J Med Biol Res 1999; 32: 1361-6.

Feron O and Michel T.  New paradigms in the post-translational regulation of the endothelial isoform of nitric oxide synthase.  Nefrologia 1998; 18:90-4.

Michel T and Feron O.  Nitric oxide synthases: which, where, why and how?  J Clin Invest, 1997, 100: 2146-52.

Sase K and Michel T.  Expression and regulation of endothelial nitric oxide synthase.  Trends in Cardiovasc Med, 1997; 7:25-34.

Robinson, LJ and Michel T.  Expression of endothelial nitric oxide synthase in heterologous cell systems.  Methods Enzymol 1996; vol 269, 55-64.

Robinson, LJ, Ghanouni P and Michel, T.  Post-translational modifications of endothelial nitric oxide synthase.  Methods in Enzymology 1996; 268:436-448.

Smith TW, Balligand JL, Kaye DM, Wiviott SD, Simmons WW, Han X, Michel T, Singh K, Kelly RA.  The role of the NO pathway in the control of cardiac function. J Cardiac Failure 1996 4:S141-7.

Michel T and Smith TW.  Nitric oxide synthases and cardiovascular signaling.  Amer J Cardiol 1993; 72:1C-6C.

Michel T.  The guide to politically correct cardiology.  J Irreprod Results1993; 38:7-8.

Michel T and Lamas S.  Molecular cloning of constitutive endothelial nitric oxide synthase: evidence for a family of related genes.  J Cardiovasc Pharmacol 1992; 20:S45-S49.

Lefkowitz RJ, Michel T.  Plasma membrane receptors.  J Clin Invest 1983; 72:1185-9.

Lefkowitz RJ, Caron MG, Michel T, Stadel JM.  Mechanisms of hormone receptor effector coupling: the beta adrenergic receptor and adenylate cyclase.  Fed Proc 1982; 41:1664-70.

Lefkowitz RJ, DeLean A, Hoffman BB, Stadel JM, Kent R, Michel T, Limbird L. Molecular pharmacology of adenylate cyclase-coupled alpha and beta adrenergic receptors.  Adv Cyclic Nucleotide Res 198; 14:145-61.